每经头条（nbdtoutiao）——处方药变"瘾品"：国内首次报告普瑞巴林滥用致成瘾病例，网络平台暴 露"无病历可购药"漏洞，列管与否尚需科学考量 （记者 王晓波） 每经AI快讯，欧普康视（SZ 300595，收盘价：15.57元）12月8日晚间发布公告称，公司第四届第二十 次董事会会议于2025年12月8日以通讯形式召开。会议审议了《关于续聘会计师事务所的议案》等文 件。 2024年1至12月份，欧普康视的营业收入构成为：硬性角膜接触镜行业占比56.18%，医疗行业占比 20.04%，其它视光与专业服务占比19.47%，非视光&其它占比4.31%。 截至发稿，欧普康视市值为139亿元。 ...

Group 1 - The core viewpoint of the article highlights the financial status and operational structure of Opcon Vision, including significant share pledges and revenue breakdowns for 2024 [1] - As of the announcement date, Nanjing Outo has pledged approximately 68.3 million shares, accounting for 67.98% of its total holdings [1] - The projected revenue composition for Opcon Vision in 2024 is as follows: 56.18% from the rigid contact lens industry, 20.04% from the medical sector, 19.47% from other optometry and professional services, and 4.31% from non-optometry and other services [1] - The current market capitalization of Opcon Vision is 15.3 billion yuan [1]